(Q36993383)

17 August 2017

1 reference

title

Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer (English)

1 reference

17 August 2017

Christa K Baumann

1

1 reference

17 August 2017

Monica Castiglione-Gertsch

series ordinal

2

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67

1 reference

17 August 2017

issue

16

1 reference

17 August 2017

page(s)

2335-2353

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767160-00004

17 August 2017

exact match

0 references

cites work

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00004

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

21 January 2018

1 reference

12 December 2020

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

12 December 2020

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

12 December 2020

Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study

1 reference

12 December 2020

Long-term Tamoxifen Therapy for the Treatment of Breast Cancer

1 reference

12 December 2020

Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.

1 reference

12 December 2020

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

12 December 2020

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

1 reference

12 December 2020

Mechanisms of tamoxifen resistance

1 reference

12 December 2020

Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand

1 reference

12 December 2020

Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

12 December 2020

Mechanisms of tamoxifen resistance

1 reference

12 December 2020

Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy

1 reference

12 December 2020

Arzoxifene: the development and clinical outcome of an ideal SERM.

1 reference

12 December 2020

Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study

1 reference

12 December 2020

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

1 reference

12 December 2020

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficac

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

12 December 2020

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group

1 reference

12 December 2020

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Bone scan flare predicts successful systemic therapy for bone metastases

1 reference

12 December 2020

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer

1 reference

12 December 2020

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

1 reference

12 December 2020

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene

1 reference

12 December 2020

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

1 reference

12 December 2020

Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene

1 reference

12 December 2020

The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

12 December 2020

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes

1 reference

12 December 2020

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Hormone receptors: their role in predicting prognosis and response to endocrine therapy

1 reference

12 December 2020

Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Stockholm Breast Cancer Study Group

1 reference

12 December 2020

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer

1 reference

12 December 2020

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

1 reference

12 December 2020

The flare phenomenon: far from fair and square

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

1 reference

12 December 2020

Multiple progesterone receptor assays in human breast cancer.

1 reference

12 December 2020

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

12 December 2020

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

1 reference

12 December 2020

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

12 December 2020

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

12 December 2020

Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience

1 reference

12 December 2020

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

1 reference

12 December 2020

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

12 December 2020

Tamoxifen versus toremifene in the adjuvant treatment of breast cancer

1 reference

12 December 2020

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

12 December 2020

Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

1 reference

12 December 2020

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

1 reference

12 December 2020

The relationship between prognostic and predictive factors in the management of breast cancer

1 reference

12 December 2020

Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?

1 reference

12 December 2020

Molecular determinants of tissue selectivity in estrogen receptor modulators

1 reference

12 December 2020

Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer

1 reference

12 December 2020

Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial

1 reference

12 December 2020

TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.

1 reference

12 December 2020

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

12 December 2020

A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up

1 reference

12 December 2020

Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer

1 reference

12 December 2020

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

1 reference

12 December 2020

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

1 reference

12 December 2020

Overview of the main outcomes in breast-cancer prevention trials

1 reference

12 December 2020

Cancer of the endometrium: current aspects of diagnostics and treatment

1 reference

12 December 2020

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

1 reference

12 December 2020

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

1 reference

12 December 2020

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up

1 reference

12 December 2020

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

12 December 2020

A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer

1 reference

12 December 2020

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

12 December 2020

Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice

1 reference

12 December 2020

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer

1 reference

12 December 2020

Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.

1 reference

12 December 2020

Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh

1 reference

12 December 2020

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer

1 reference

12 December 2020

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials

1 reference

12 December 2020

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

1 reference

12 December 2020

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

12 December 2020

The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.

1 reference

12 December 2020

Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage

1 reference

12 December 2020

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation

1 reference

12 December 2020

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

1 reference

12 December 2020

Molecular determinants for the tissue specificity of SERMs

1 reference

12 December 2020

The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial

1 reference

12 December 2020

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

1 reference

12 December 2020

Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Raloxifene reduces fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

1 reference

12 December 2020

A potent specific pure antiestrogen with clinical potential

1 reference

12 December 2020

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters

1 reference

12 December 2020

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

1 reference

12 December 2020

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

1 reference

12 December 2020

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

12 December 2020

TAS-108: a novel steroidal antiestrogen.

1 reference

12 December 2020

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Structural insights into the mode of action of a pure antiestrogen

1 reference

12 December 2020

The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00003495-200767160-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1036378906

0 references

1 reference